A Randomized, Single-Blind, Crossover Study Evaluating the Impact of OnabotulinumtoxinA Treatment on Mood and Appearance During the COVID-19 Pandemic
| Autor: | Eljona Kola, Tariq Z Issa, Robert T. Cristel, Steven H. Dayan, Nimit D Gandhi, Daniel Demesh |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Coronavirus disease 2019 (COVID-19) media_common.quotation_subject Context (language use) Disease 030230 surgery Treatment and control groups 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Pandemic medicine Humans Single-Blind Method Botulinum Toxins Type A Pandemics media_common Cross-Over Studies AcademicSubjects/MED00987 SARS-CoV-2 business.industry COVID-19 General Medicine Crossover study Mood Physical therapy Happiness Original Article Surgery business |
| Zdroj: | Aesthetic Surgery Journal |
| ISSN: | 1527-330X 1090-820X |
| DOI: | 10.1093/asj/sjab196 |
| Popis: | Background The emergence of COVID-19 led rapidly to one of the most severe disease outbreaks in modern history. This caused many aesthetic practices to close temporarily, providing a unique opportunity to evaluate the impact of neurotoxin use in the setting of an ongoing pandemic. Objectives The aim of this study was to examine whether administration of onabotulinumtoxinA (BOTOX Cosmetic, Allergan plc, Dublin, Ireland) to regular users synergistically amplifies the elevation in mood/happiness, self-satisfaction with appearance, and overall satisfaction in the context of the ongoing pandemic. Methods A randomized, single-blind, crossover study was designed to evaluate the impact of neurotoxin treatment in the upper third of the face on mood, self-satisfaction with appearance, and overall satisfaction. The placebo group crossed over to treatment after 1 month. Surveys evaluating patient happiness, self-satisfaction with appearance, and overall efficacy were completed by both groups, and again by the placebo group following crossover to treatment. Results Forty-five subjects were enrolled: 30 in the treatment group and 15 in the control/crossover group. The placebo group demonstrated no change in happiness or self-satisfaction in appearance until crossover to the treatment group. Both groups, once receiving onabotulinumtoxinA, reported increased happiness, self-satisfaction with appearance, and overall treatment satisfaction. Conclusions OnabotulinumtoxinA treatment to the upper face in the midst of the COVID-19 pandemic was found to increase patient happiness, self-satisfaction with appearance, and overall treatment satisfaction. Level of Evidence: 2 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|